kt 6149 has been researched along with Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ardiet, C; Catimel, G; De Bruijn, E; Dirix, L; Dumortier, A; Evene, E; Joossens, E; Koier, I; Provè, A; Schrijvers, D | 1 |
| Catimel, G; De Bruijn, E; Dirix, L; Droz, JP; Highley, M; Höppener, FJ; Schrijvers, D; Van Oosterom, AT | 1 |
2 trial(s) available for kt 6149 and Neoplasms
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biotransformation; Bone Marrow Diseases; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Diseases; Half-Life; Humans; Liver Neoplasms; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Mitomycin; Mitomycins; Neoplasms; Neoplasms, Unknown Primary; Salvage Therapy | 1995 |
KW-2149-induced pulmonary toxicity is not prevented by corticosteroids: a phase I and pharmacokinetic study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antibiotics, Antineoplastic; Digestive System; Female; Humans; Kidney; Liver; Lung; Male; Middle Aged; Mitomycins; Neoplasms | 1999 |